Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)

被引：32

作者：

Feuerstein, Joseph D. ^{[1
]}

Cheifetz, Adam S. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Dept Med,Ctr Inflammatory Bowel, Boston, MA 02215 USA

来源：

GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2014年 / 43卷 / 03期

关键词：

Anti-tumor necrosis factor; Infliximab; Adalimumab; Golimumab; Certolizumab pegol; Complications; Infusion reactions; Autoimmune disease; NECROSIS-FACTOR-ALPHA; INFLAMMATORY-BOWEL-DISEASE; LUPUS-LIKE SYNDROME; ANTI-TNF THERAPY; CROHNS-DISEASE; RHEUMATOID-ARTHRITIS; VENOUS THROMBOEMBOLISM; AUTOIMMUNE HEPATITIS; MULTIPLE-SCLEROSIS; INFUSION REACTIONS;

D O I：

10.1016/j.gtc.2014.05.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Anti-tumor necrosis factor-a (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration-approved for moderate to severe IBD: infliximab, adalimumab, golimumab, and certolizumab pegol. For most noninfectious, nonmalignant adverse events, cessation of anti-TNF therapy typically leads to improvement or resolution of drug-induced complications. In this article, the current knowledge regarding the noninfectious and nonmalignant toxicities associated with anti-TNF agents is summarized.

引用

页码：543 / +

页数：22

共 109 条

[1]

Adar Tomer, 2010, J Clin Gastroenterol, V44, pe20, DOI 10.1097/MCG.0b013e3181a745e7

[2] Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study [J].

Andersen, Nynne Nyboe ;

Caspersen, Sarah ;

Jess, Tine ;

Munkholm, Pia .

JOURNAL OF CROHNS & COLITIS, 2008, 2 (04) :304-309

[3] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[4] Systematic Review and Meta-Analysis: Anti-Tumor Necrosis Factor α Therapy and Cardiovascular Events in Rheumatoid Arthritis [J].

Barnabe, Cheryl ;

Martin, Billie-Jean ;

Ghali, William A. .

ARTHRITIS CARE & RESEARCH, 2011, 63 (04) :522-529

[5] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Genovese, MC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593

[6] Etanercept tolerance in a patient with previous infliximab-induced hepatitis [J].

Becker, Heidemarie ;

Willeke, Peter ;

Domschke, Wolfram ;

Gaubitz, Markus .

CLINICAL RHEUMATOLOGY, 2008, 27 (12) :1597-1598

[7] Formation of Antinuclear and Double-strand DNA Antibodies and Frequency of Lupus-like Syndrome in Anti-TNF-α Antibody-treated Patients with Inflammatory Bowel Disease [J].

Beigel, Florian ;

Schnitzler, Fabian ;

Laubender, Ruediger Paul ;

Pfennig, Simone ;

Weidinger, Maria ;

Goeke, Burkhard ;

Seiderer, Julia ;

Ochsenkuehn, Thomas ;

Brand, Stephan .

INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) :91-98

[8] Multiple sclerosis in Mostoles, central Spain [J].

Benito-Leon, J ;

Martin, E ;

Vela, L ;

Villar, ME ;

Felgueroso, B ;

Marrero, C ;

Guerrero, A ;

Ruiz-Galiana, J .

ACTA NEUROLOGICA SCANDINAVICA, 1998, 98 (04) :238-242

[9] The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study [J].

Bernstein, CN ;

Wajda, A ;

Blanchard, JF .

GASTROENTEROLOGY, 2005, 129 (03) :827-836

[10] Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy [J].

Bessissow, T. ;

Renard, M. ;

Hoffman, I. ;

Vermeire, S. ;

Rutgeerts, P. ;

Van Assche, G. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (04) :312-323

← 1 2 3 4 5 6 7 8 9 10 →